Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
MitMAB for Endocytosis Research in Organoids
2026-10-01
MitMAB provides a practical way to test whether dynamin-dependent membrane scission contributes to extracellular vesicle uptake in polarized intestinal models. Its value is greatest when paired with region-specific organoids, matched vehicle controls, viability checks, and orthogonal trafficking readouts.
Firefly Luciferase mRNA: Assay Workflows
2026-10-01
Build reproducible translation, transfection, cell viability, and imaging workflows with a capped, modified Firefly Luciferase mRNA reporter. The guide connects practical assay design with a human tripartite cell-free translation strategy, helping distinguish RNA delivery, transcript stability, and ribosome-dependent protein synthesis.
Linagliptin (BI-1356): A Rigorous Assay Guide
2026-09-30
Linagliptin (BI-1356) is best understood as a DPP-4-directed pharmacological tool, not a substitute for NUAK inhibition. This guide explains how to position it responsibly in tau and Alzheimer’s disease experiments informed by p-tau Ser356 evidence.
Sulfisomidine: hPON1 Assay Workflows
2026-09-30
Sulfisomidine, also known as sulfamethin, is a practical probe for mixed-type hPON1 inhibition and PABA-dependent antibacterial research. This workflow-focused guide covers stock preparation, kinetic experiment design, cross-domain applications, and troubleshooting for reproducible in vitro studies.
EdU Imaging Kits (488) for S-Phase Assays
2026-09-29
EdU Imaging Kits (488) convert DNA replication into a high-contrast fluorescence readout without the DNA denaturation required by BrdU workflows. The assay is especially useful for connecting drug exposure to S-phase suppression, cell-cycle arrest, senescence, and apoptosis in cancer models.
ROS-Driven Metabolic Rewiring in BRAF Melanoma
2026-09-29
Cesi et al. show that BRAF or MEK pathway inhibition increases reactive oxygen species, activates pyruvate dehydrogenase kinases, and suppresses PDH-dependent oxidative metabolism in melanoma cells. The study identifies PDK inhibition as a potentially actionable vulnerability, including in BRAF inhibitor-resistant models, while providing a mechanistic framework for understanding metabolic adaptation during targeted therapy.
Hydroxycinnamic Acids, COPII, and cGAS-STING
2026-09-28
The reference study identifies the Sec24 B-site of the COPII coat complex as a molecular target of cinnamic, caffeic, and ferulic acids, linking hydroxycinnamic acid activity to disrupted STING trafficking. Its structural, cellular, and diabetic-mouse data provide a mechanistic framework for understanding how these compounds reduce hepatic steatosis, inflammatory signaling, and metabolic dysfunction.
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-28
Masitinib (AB1010) is a DMSO-soluble tyrosine kinase inhibitor for investigating KIT and PDGFR signaling, including in cancer, mast cell, and inflammatory models. Use it in controlled, target-relevant research workflows; it is not suited to water- or ethanol-based protocols, and research results should not be treated as clinical guidance.
gamma-Glu-Cys (γ-Glu-Cys) Workflow Guide
2026-09-27
gamma-Glu-Cys (γ-Glu-Cys) is a defined intermediate for glutathione metabolism research and glutathione synthetase enzyme assays. This guide covers practical handling and assay setup; the material is for controlled scientific research and is not intended for diagnostic or medical use.
Exo1 Workflows for Trafficking and EV Research
2026-09-26
Exo1 offers a rapid way to probe Golgi–ER traffic and exocytosis, with a mechanism distinct from Brefeldin A. This guide lays out a practical cell-based workflow and explains how to explore extracellular-vesicle questions without mistaking a research hypothesis for a validated Exo1 application.
Fenofibrate Workflows for PPARα and YAP Research
2026-09-25
Use Fenofibrate to probe PPARα-driven lipid metabolism and connect receptor activation with YAP-associated liver growth in age-aware experimental designs. This workflow pairs practical solubility and control guidance with clear limits for interpreting cytotoxicity and cross-domain findings.
Triiodothyronine (T3): Practical Assay Workflows
2026-09-25
Build more interpretable thyroid hormone signaling experiments with a practical T3 workflow for dose selection, controls, and metabolic readouts. A recent base-editing study offers a useful assay-design lesson about cellular context—without implying a direct connection between gene editing and thyroid hormone biology.
SFTSV NSs Disrupts the DPP9 Inflammasome Checkpoint
2026-09-24
The study finds that SFTSV non-structural protein NSs activates NLRP1 in primary keratinocytes and CARD8 in macrophages by targeting the DPP8/9-mediated inhibitory complex. Its mechanistic model connects NSs binding to sensor FIIND domains with DPP8/9 degradation, and identifies CARD8 as a restriction factor for viral replication in the tested system.
PP2A, Autophagy, and Candida Biofilm Drug Resistance
2026-09-24
A 2025 study links the PP2A catalytic subunit gene PPH21 to autophagy induction, biofilm formation, and antifungal resistance in Candida albicans. Its mutant and mouse oral-infection findings suggest that disrupting this regulatory connection may improve antifungal response, although the precise phosphorylation mechanism and its transfer to other infection models require further testing.
IR-820 (New Indocyanine Green): Assay-Safe Use
2026-09-23
Learn how to use IR-820 (New Indocyanine Green), SKU C8228, as an in vivo near-infrared imaging dye without mistaking optical signal for cell viability or therapeutic evidence. Five laboratory scenarios cover assay compatibility, handling, interpretation, and practical product selection.
8333 records 6/556 page Previous Next First page 上5页 678910 下5页 Last page